OUR PRODUCTS

Through a third-generation screening, we
have identified molecules that have been validated at the preclinical stage for the treatment of Rett syndrome and CDKL5 deficiency disorder.

We are currently testing these molecules in iPSC-derived neurons and organoids and animal models. Our approach can be used to develop therapeutics for any X-linked or autosomal disease genes. We have applied for two European patents to protect our unique approach and for the protection of therapeutic XCI-reactivating molecules.